UAE Antibody Drug Conjugates Market Size & Outlook
UAE antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
UAE antibody drug conjugates market highlights
- The UAE antibody drug conjugates market generated a revenue of USD 9.0 million in 2021 and is expected to reach USD 49.7 million by 2030.
- The UAE market is expected to grow at a CAGR of 20.9% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 9.0 million |
| Market revenue in 2030 | USD 49.7 million |
| Growth rate | 20.9% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, UAE accounted for 0.2% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 95.7 million by 2030.
Breast cancer was the largest segment with a revenue share of 55.56% in 2021. Horizon Databook has segmented the UAE antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Rise in adoption of modern lifestyle patterns has led to an increase in demand for specialized care for oncological diseases in the UAE. The country is already well-equipped in providing advanced treatments for the same through sufficient expertise.
Gilead Life Science’s drug Trodelyv was the first ADC drug to be approved by the FDA for treating people with metastatic triple-negative breast cancer. Due to the high prevalence of breast cancer and presence of leading companies in the country, the market for ADC drugs in the UAE is expected to grow over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UAE antibody drug conjugates market size, by application, 2018-2030 (US$M)
UAE Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
